Patents by Inventor Joyce M Zarling
Joyce M Zarling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6384198Abstract: An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric nonclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional non-HIV-1-producing T cells in the patient.Type: GrantFiled: May 31, 1995Date of Patent: May 7, 2002Assignee: Bristol-Myers Sqibb CompanyInventors: Michael L Diegel, Peter S Linsley, Lisa K Gilliland, Patricia A Moran, Joyce M Zarling, Jeffrey A Ledbetter
-
Patent number: 5807734Abstract: An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.Type: GrantFiled: May 31, 1995Date of Patent: September 15, 1998Assignee: Bristol-Myers Squibb CompanyInventors: Michael L. Diegel, Peter S. Linsley, Lisa K. Gilliland, Patricia A. Moran, Joyce M. Zarling, Jeffrey A. Ledbetter
-
Patent number: 5795572Abstract: An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric monoclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional, non-HIV-1-producing T cells in the patient.Type: GrantFiled: May 25, 1993Date of Patent: August 18, 1998Assignee: Bristol-Myers Squibb CompanyInventors: Michael L. Diegel, Peter S. Linsley, Lisa K. Gilliland, Patricia A. Moran, Joyce M. Zarling, Jeffrey A. Ledbetter
-
Patent number: 5618715Abstract: Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.Type: GrantFiled: June 10, 1993Date of Patent: April 8, 1997Assignee: Oncogen Limited PartnershipInventors: Mohammed Shoyab, Joyce M. Zarling, Hans Marquardt, Marcia B. Hanson, Najma Malik, Peter S. Linsley, Timothy M. Rose, Anthony F. Purchio
-
Patent number: 5451506Abstract: Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.Type: GrantFiled: June 16, 1993Date of Patent: September 19, 1995Assignee: Oncogen Limited PartnershipInventors: Mohammed Shoyab, Joyce M. Zarling, Hans Marquardt, Marcia B. Hanson, Peter S. Linsley
-
Patent number: 5428012Abstract: Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.Type: GrantFiled: July 1, 1993Date of Patent: June 27, 1995Assignee: Oncogen Limited PartnershipInventors: Mohammed Shoyab, Joyce M. Zarling, Hans Marquardt, Marcia B. Hanson, Thomas J. Brown
-
Patent number: 5120535Abstract: Novel compositions are provided for modulating growth, particularly of tumor cells, which compositions are combinations of Oncostatin M, and one or both of transforming growth factors or .gamma.-interferons, or analogs thereof. In addition, a novel transforming growth factor is provided, designated TGF-.beta.2, as well as methods for its preparation.Type: GrantFiled: May 4, 1987Date of Patent: June 9, 1992Assignee: OncogenInventors: Hans Marquardt, Joyce M. Zarling, Mohammed Shoyab, Marcia B. Hanson, Mario N. Lioubin, Thomas J. Brown, Tatsuhiko Ikeda
-
Patent number: 5081029Abstract: Immunotherapeutic methods for the treatment of patients infected with the AIDS virus are described. T lymphocytes which are histocompatible with the patient and specific for the AIDS virus are activated in vitro by exposure to AIDS virus-related epitopes. Activated T lymphocytes are expanded and inoculated into the patient in order to transfer T cell immunity directed against the AIDS virus epitopes.Type: GrantFiled: February 1, 1989Date of Patent: January 14, 1992Assignee: OncogenInventors: Joyce M. Zarling, Shiu-Lok Hu